Status | Study |
RECRUITING |
Study Name: A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis Condition: Dermatomyositis Date: 2023-01-13 Interventions: GLPG3667 capsules will be administered per dose and schedule specified in the arm description. |
RECRUITING |
Study Name: Study of M5049 in DM and PM Participants (NEPTUNIA) Condition: Dermatomyositis Date: 2022-12-06 Interventions: Participants will receive film-coated tablets of M5049 at a high dose orally, twice daily up to 24 weeks. |
Recruiting |
Study Name: Study of Tofacitinib in Refractory Dermatomyositis Condition: Dermatomyositis Date: 2016-12-20 Interventions: Drug: Tofacitinib Tofacitinib comes as an extended-release (XR) (long-acting) tablet to take by mouth. T |
Recruiting |
Study Name: Study of IFN-K in Dermatomyositis Condition: Dermatomyositis Date: 2016-11-25 Interventions: Biological: IFN-Kinoid Other: Placebo |
Recruiting |
Study Name: Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) Condition: Dermatomyositis Date: 2016-03-11 Interventions: Drug: Octagam 10% Patients to |
Recruiting |
Study Name: Trial of IMO-8400 in Adult Patients With Dermatomyositis Condition: Dermatomyositis Date: 2015-11-18 Interventions: Drug: IMO-8400 Dose Group 1 IM |
Recruiting |
Study Name: Abatacept in Juvenile Dermatomyositis Condition: Dermatomyositis Date: 2015-10-21 Interventions: Drug: Abatacept Study participation will consist of a screening visit and 5 protocol visits over six mon |
Recruiting |
Study Name: Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis Condition: Dermatomyositis Date: 2015-06-02 Interventions: Drug: JBT-101 Part A: 20 mg on |
Recruiting |
Study Name: Subcutaneous Immunoglobulin (Hizentra) in Patients With Dermatomyositis: A Proof of Concept Study Condition: Dermatomyositis Date: 2014-10-15 Interventions: Drug: Immunoglobulin (Hizentra) Other Name: Immunoglobulin subcutaneous (human) 20% liquid, Hizentra |
Recruiting |
Study Name: Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Condition: Dermatomyositis Juvenile Dermatomyositis Date: 2014-09-11 Interventions: Drug: H.P. Acthar Gel 80 U (1 mL) of H.P. Acthar gel via subcutaneous injection twice weekly for 24 week |